Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $2.1 million.

  • Coherus Oncology's Other Non Operating Income rose 273.51% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 16698.69%. This contributed to the annual value of -$12.6 million for FY2024, which is 33093.8% down from last year.
  • As of Q3 2025, Coherus Oncology's Other Non Operating Income stood at $2.1 million, which was up 273.51% from $2.9 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Other Non Operating Income high stood at $2.9 million for Q2 2025, and its period low was -$12.6 million during Q2 2024.
  • Over the past 5 years, Coherus Oncology's median Other Non Operating Income value was $443000.0 (recorded in 2022), while the average stood at -$100117.6.
  • Data for Coherus Oncology's Other Non Operating Income shows a peak YoY increase of 436333.33% (in 2022) and a maximum YoY decrease of 1030000.0% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Coherus Oncology's Other Non Operating Income stood at -$385000.0 in 2021, then soared by 447.79% to $1.3 million in 2022, then tumbled by 109.63% to -$129000.0 in 2023, then surged by 1715.5% to $2.1 million in 2024, then increased by 2.74% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.9 million for Q2 2025, and $187000.0 during Q1 2025.